{"id":"humalog-mix25","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination insulin product delivers 25% rapid-acting insulin lispro (which begins working within 15 minutes) and 75% NPH insulin (intermediate-acting, peaking at 4-8 hours). The dual-component formulation allows for a single injection that addresses both postprandial (after-meal) glucose spikes and basal glucose control, simplifying the insulin regimen for patients with type 1 or type 2 diabetes.","oneSentence":"Humalog® Mix25 is a premixed insulin formulation combining rapid-acting insulin lispro with intermediate-acting insulin isophane to provide both immediate and sustained blood glucose control.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:48:01.026Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05373186","phase":"PHASE1","title":"A Trial Investigating the Pharmacodynamics of BC Combo THDB0207 Compared With Humalog® Mix25 and Simultaneous Injections of Humalog® and Lantus® in Healthy Chinese Volunteers","status":"COMPLETED","sponsor":"Adocia","startDate":"2022-05-12","conditions":"Healthy","enrollment":27},{"nctId":"NCT05373212","phase":"PHASE1","title":"A Trial Investigating the Dose Linearity and Safety of BC Combo THDB0207 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Adocia","startDate":"2022-05-12","conditions":"Type 2 Diabetes","enrollment":40},{"nctId":"NCT04023344","phase":"PHASE3","title":"Efficacy and Safety of Insulin Lispro Biphasic 25 Compared to Humalog® Mix 25 in Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Geropharm","startDate":"2018-03-14","conditions":"Diabetes Mellitus, Type 2, Diabetes Mellitus","enrollment":210},{"nctId":"NCT03606018","phase":"NA","title":"A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Lispro Mix 25 to Humalog® Mix 25 in Healthy Subjects","status":"COMPLETED","sponsor":"Geropharm","startDate":"2017-04-12","conditions":"Clamp Study","enrollment":48},{"nctId":"NCT03180710","phase":"PHASE1","title":"A Trial to Investigate the Dose-linearity of BioChaperone® Combo 75/25 and the Safety at Three Different Doses in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Adocia","startDate":"2017-06-06","conditions":"Type 2 Diabetes Mellitus","enrollment":32},{"nctId":"NCT02915250","phase":"PHASE1","title":"A Trial to Compare Post Prandial Blood Glucose Control of BioChaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Adocia","startDate":"2016-10","conditions":"Type 2 Diabetes Mellitus","enrollment":36},{"nctId":"NCT01981031","phase":"PHASE1","title":"A Trial to Assess the Efficacy and Safety of BioChaperone Combo and Humalog Mix 25 in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Adocia","startDate":"2013-11","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":21},{"nctId":"NCT02514850","phase":"PHASE1","title":"A Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Adocia","startDate":"2015-07","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT02514954","phase":"PHASE1","title":"Postprandial Blood Glucose Control With BioChaperone® Combo and Insulin Lispro (Humalog®) Mix 25 in People With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Adocia","startDate":"2015-07","conditions":"Type 1 Diabetes Mellitus","enrollment":28},{"nctId":"NCT01147627","phase":"NA","title":"Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2010-08","conditions":"Diabetes Mellitus, Type 2, Newly Diagnosed","enrollment":416},{"nctId":"NCT00806975","phase":"NA","title":"Comparison of Novo Rapid 30 Mix Injection FlexPen® and Humalog 25 Mix Injection KwikPen® in Type 2 Diabetic Patients","status":"UNKNOWN","sponsor":"Nagaoka Red Cross Hospital","startDate":"2009-01","conditions":"Diabetes Complications, Diabetes Mellitus, Type 2","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Humalog® Mix25","genericName":"Humalog® Mix25","companyName":"Adocia","companyId":"adocia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Humalog® Mix25 is a premixed insulin formulation combining rapid-acting insulin lispro with intermediate-acting insulin isophane to provide both immediate and sustained blood glucose control. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}